“Our strategy of optimising our product offering with a focus on key brands has begun to bear fruit as reflected in the 14 per cent sequential growth (QoQ) with sales of Rs 112 crore in Q1FY16,” said Kiran Mazumdar-Shaw, Chairperson and Managing Director, Biocon, commenting on the company’s quarterly performance.

“This performance was led by the Metabolics, Nephrology and Market Access divisions. We continue to grow well in the addressable insulins market, with a growth of 20 per cent, against the market growth of 14 per cent. CANMAb, our affordable biosimilar Trastuzumab, continues to gain traction as a life-saving therapy for HER2-positive metastatic breast cancer patients,” she added.

Novel Molecules

A scientific paper titled ‘Long-term Efficacy and Safety of Itolizumab in Patients with Moderate-to-Severe Chronic Plaque Psoriasis,’ authored by Dr Sunil Dogra, Additional Professor from PGI Chandigarh with other opinion leaders in dermatology and Biocon’s R&D team, has been published in the prestigious Journal of American Academy of Dermatology , which profiles the unique attributes of our novel anti-CD6 monoclonal antibody leading to positive patient outcomes.

Biopharmaceuticals

The biopharmaceuticals segment benefitted from a strong contribution from our Insulins and biosimilars business in the emerging markets.

“Our partner, Denmark-headquartered Veloxis, received USFDA approval for its proprietary Envarus XR formulation (tacrolimus extended release tablets) for prophylactic use in kidney transplant patients,” said Mazumdar-Shaw.

“We have established a new entity, Biocon Pharma Ltd, to support our finished dosage generics business. We see this as an important future growth driver,” she added.

Related Topics
comment COMMENT NOW